Swelling

Seat Occupancy Sensors and Gaming - IDTechEx Explores Printed and Flexible Sensors

Retrieved on: 
Friday, May 3, 2024
System, Glass, Temperature, Swelling, Flexible, Market, Heart rate, Tablet, Pressure, Growth, Overheating, Players

They measure all sorts of variables from touch, temperature, and heart rate across many different sectors, which IDTechEx's report " Printed and Flexible Sensors 2024-2034: Technologies, Players, Markets " explores in detail.

Key Points: 
  • They measure all sorts of variables from touch, temperature, and heart rate across many different sectors, which IDTechEx's report " Printed and Flexible Sensors 2024-2034: Technologies, Players, Markets " explores in detail.
  • Battery health monitoring in electric vehicles using multi-functional hybrid sensors is an emerging role for printed and flexible sensors.
  • Gaming controllers and inputs could be revolutionized with printed flexible 3D force sensors.
  • To find out more about the IDTechEx report "Printed and Flexible Sensors 2024-2034: Technologies, Players, Markets", including downloadable sample pages, please visit www.IDTechEx.com/flexsensors .

Seat Occupancy Sensors and Gaming - IDTechEx Explores Printed and Flexible Sensors

Retrieved on: 
Friday, May 3, 2024
System, Glass, Temperature, Swelling, Flexible, Market, Heart rate, Tablet, Pressure, Growth, Overheating, Players

They measure all sorts of variables from touch, temperature, and heart rate across many different sectors, which IDTechEx's report " Printed and Flexible Sensors 2024-2034: Technologies, Players, Markets " explores in detail.

Key Points: 
  • They measure all sorts of variables from touch, temperature, and heart rate across many different sectors, which IDTechEx's report " Printed and Flexible Sensors 2024-2034: Technologies, Players, Markets " explores in detail.
  • Battery health monitoring in electric vehicles using multi-functional hybrid sensors is an emerging role for printed and flexible sensors.
  • Gaming controllers and inputs could be revolutionized with printed flexible 3D force sensors.
  • To find out more about the IDTechEx report "Printed and Flexible Sensors 2024-2034: Technologies, Players, Markets", including downloadable sample pages, please visit www.IDTechEx.com/flexsensors .

"A New Era in Venous Care: Bowie Welcomes Vein Treatment Clinic"

Retrieved on: 
Tuesday, April 30, 2024
Radiofrequency ablation, Mouth ulcer, Patient, RFA, Swelling, Education, Vein, Oberlin College, Itch, Varicose veins, Female, Environment, Physician, Weight, Cramp, General surgery

BOWIE, Md., April 30, 2024 /PRNewswire/ -- A pioneering vein treatment facility, Vein Treatment Clinic is delighted to announce its grand opening in Bowie, Maryland , offering revolutionary vascular care and innovative treatment solutions to the community.

Key Points: 
  • BOWIE, Md., April 30, 2024 /PRNewswire/ -- A pioneering vein treatment facility, Vein Treatment Clinic is delighted to announce its grand opening in Bowie, Maryland , offering revolutionary vascular care and innovative treatment solutions to the community.
  • Vein Treatment Clinic is dedicated to the comprehensive management and treatment of various venous disorders, including varicose veins, spider veins, venous ulcers, and more.
  • Per Dr. Kamran Saraf, "At the Vein Treatment Clinic, we are committed to excellence in vein care with minimal discomfort or downtime."
  • For additional information about the Vein Treatment Clinic or to book a consultation, please visit www.veintreatmentclinic.com or contact the clinic directly at 240-219-8778.

Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Retrieved on: 
Monday, April 29, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Other Health, Dermatitis, Itch, Pain, Shanda, Skin, Inflammation, Food, Swelling, Stinger, Rash, Body surface area, Nose, Agency, Atopic dermatitis, Folliculitis, Common, Therapy, PDUFA, Incidence, Patient, Psoriasis, Red, Headache, Irritation, Ageing, Pharmaceutical industry

The Prescription Drug User Fee Act ("PDUFA") action date assigned by the Agency is in Q4 2024.

Key Points: 
  • The Prescription Drug User Fee Act ("PDUFA") action date assigned by the Agency is in Q4 2024.
  • VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of AD.
  • On May 24, 2022, Dermavant announced the FDA approved VTAMA® (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults.
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Retrieved on: 
Wednesday, April 17, 2024
Health, FDA, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Pain, American Academy, Phase, ARR, OCR, News, Blood, Swelling, Food, ROG, American Academy of Neurology, Erythema, Inflammation, Roche, Disease, Patient, RMS, Neurology, AAN, EMA, Itch, MRI, PPMS, Irritation, Annual general meeting, Food and Drug Administration, European Medicines Agency, Disability, Pharmaceutical industry

Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigational formulation.

Key Points: 
  • Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigational formulation.
  • “Updated results from OCARINA II further underline the potential benefits of subcutaneous Ocrevus for patients with both relapsing and progressive forms of MS,” said Scott Newsome, D.O., lead author, Johns Hopkins University School of Medicine.
  • “Patients treated with subcutaneous Ocrevus experienced appropriate B-cell suppression and impressive near-complete suppression of new inflammatory disease activity.
  • There are more than 30 ongoing Ocrevus clinical trials designed to help us better understand MS and its progression.

NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists

Retrieved on: 
Wednesday, April 10, 2024
Health Technology, Other Health, Technology, Pharmaceutical, Oncology, Mental Health, Philanthropy, Infectious Diseases, Genetics, Artificial Intelligence, Clinical Trials, Foundation, Biotechnology, Science, Research, Health, Eosinophilia, Bronchial hyperresponsiveness, NIMML, Swelling, Choline, PBMC, Gastrointestinal tract, Macrophage, Fibrosis, Red, Atopic dermatitis, Brain, TNF, Inflammation, Phenotype, Abstract, Glycolysis, Lupus, T helper 17 cell, IBD, AAI, Psoriasis, OVA, MASH, Plasma, Fed, Ulcerative colitis, Mouse, COL1A1, Microglia, McCormick Place, Therapy, Carbon tetrachloride, HDM, Immunoglobulin E, IL-6, Medicine, Asthma, House, Neutrophil, Patient, Phagocytosis, Ovalbumin, Rheumatoid arthritis, LANCL2, CDAA, UC

The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.

Key Points: 
  • The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.
  • “We are pleased to present our most recent findings related to the immunometabolic mechanisms of activation of LANCL receptors in inflammation & immunology at this year’s AAI Annual Meeting,” said Dr. Josep Bassaganya-Riera, President and Founding Director of NIMML.
  • NImmune’s portfolio includes first and best-in-class omilancor and NIM-1324, two oral, once-daily agonistic therapeutics that bind and activate the LANCL2 pathway.
  • Title: Pharmacological activation of LANCL2 provides immunometabolic support for the restoration of cognitive function markers in a mouse model of Alzheimer’s disease.

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Wednesday, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Wednesday, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

InventHelp Inventor Develops New Earring to Help Heal Infected Piercing (SGJ-252)

Retrieved on: 
Wednesday, April 17, 2024
Suite, Sale, Multimedia, ICE, Red, Swelling, Petroleum jelly

PITTSBURGH, April 17, 2024 /PRNewswire/ -- "I wanted to create an earring that could apply antibacterial ointment to help heal infected piercings," said an inventor, from Cottonwood Heights, Utah, "so I invented the STERIL ICE.

Key Points: 
  • PITTSBURGH, April 17, 2024 /PRNewswire/ -- "I wanted to create an earring that could apply antibacterial ointment to help heal infected piercings," said an inventor, from Cottonwood Heights, Utah, "so I invented the STERIL ICE.
  • My design could help reduce and possibly eliminate pain, redness, swelling, and oozing blood or pus."
  • As a result, it helps heal infected or irritated piercings.
  • 22-SGJ-252, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Nexamp Raises $520M to Power Clean Energy Mission

Retrieved on: 
Wednesday, April 10, 2024
Diamond, Bank of America, Generate, Investment, Swelling, Partnership, Engineering, Acquisition, Inflation, BofA Securities, Community, Growth, IRA, CO, Renewable energy

BOSTON, April 10, 2024 /PRNewswire/ -- Nexamp, a leading independent renewable energy provider and the nation's largest community solar developer and owner, announced today that it has secured $520 million in a capital raise led by Manulife Investment Management, alongside existing investors Diamond Generating Corporation and Generate Capital. The company will leverage the investment to expedite deployment of its national project pipeline, accelerate expansion and developer partnerships in new and existing markets, and fuel the continued growth of its generation and consumer-driven offerings.     

Key Points: 
  • The scale of the investment reflects the immense surge in demand for renewable power across the country and a growing appreciation within the investor community of the essential need to balance utility-scale infrastructure with reliable distributed power solutions in navigating the clean energy transition.
  • "This landmark financing comes at a pivotal moment in the evolution of America's energy economy, and underscores the indispensable role of community solar in democratizing access to clean, affordable energy solutions for every American," said Nexamp CEO Zaid Ashai.
  • "This unprecedented investment reflects swelling confidence in the ability of independent renewable energy providers to reimagine outmoded infrastructure and reshape our grid.
  • "Nexamp has been at the forefront of a distributed energy revolution in the United States, and we're thrilled to expand our partnership."